Stocks and Investing
Stocks and Investing
Fri, August 12, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Geulah Livshits Maintained (TSHA) at Strong Buy with Decreased Target to $32 on, Aug 12th, 2022
Geulah Livshits of Chardan Capital, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Strong Buy with Decreased Target from $34 to $32 on, Aug 12th, 2022.
Geulah has made no other calls on TSHA in the last 4 months.
There are 2 other peers that have a rating on TSHA. Out of the 2 peers that are also analyzing TSHA, 0 agree with Geulah's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Geulah
- Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $16 on, Tuesday, May 24th, 2022
- Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, May 17th, 2022
Contributing Sources